Introduction {#sec1-0300060515618053}
============

Meningiomas are the second most common primary intracranial neoplasms.^[@bibr1-0300060515618053]^ Most are benign tumours, with a low rate of recurrence after total resection.^[@bibr2-0300060515618053]^ However, it has been reported that 2--10% of meningiomas exhibit aggressive behaviour and 0.1--1% of all patients with primary meningiomas develop distant metastases.^[@bibr2-0300060515618053][@bibr3-0300060515618053]--[@bibr4-0300060515618053]^ The most frequent site for extracranial metastases is the lung, accounting for 61% of all meningioma metastases.^[@bibr5-0300060515618053]^ Here we report a rare case of multiple pulmonary metastases from a recurrent intracranial meningioma, together with a review of previous similar cases reported in the literature.

Case report {#sec2-0300060515618053}
===========

A previously healthy 56-year-old man was admitted to the Department of Neurosurgery, First Affiliated Hospital, Zhejiang, China, in June 2009 with dizziness and blurred vision for about 1 month. Magnetic resonance imaging (MRI) revealed a 4 × 4 × 5 cm homogeneously enhancing tumour in the left occiput with adjacent brain parenchymal oedema, which was suggestive of a meningioma ([Figure 1](#fig1-0300060515618053){ref-type="fig"}). Other laboratory and imaging examinations, including chest X-radiography and abdominal B-scan ultrasound, did not show any abnormalities. Figure 1.Preoperative magnetic resonance imaging in a male patient with intracranial meningioma: T1-weighted with contrast medium showing a homogeneously enhancing tumour in the left occiput: (a) axial; (b) sagittal; (c) coronal views. (d) Normal chest X-radiography taken before the first craniotomy in 2009.

The patient underwent total resection of the tumour. Histological examination of the mass revealed sheet-like growth and lobular arrangement of the tumour cells, with atypia and mitotic figures ([Figure 2a](#fig2-0300060515618053){ref-type="fig"}); the skull was invaded locally and blood sinusoids were seen in the interstitial tissue. Immunohistochemical staining demonstrated that the tumour cells were positive for vimentin, epithelial membrane antigen, Ki-67 (\>25%) and progesterone receptor, but negative for S100. Pathological examination confirmed the diagnosis of atypical meningioma (World Health Organization grade II).^[@bibr6-0300060515618053]^ Subsequently, the patient underwent adjuvant radiotherapy to help prevent recurrence. The postoperative course was uneventful and the patient's preoperative dizziness and blurred vision abated. Figure 2.Histopathology of resected tumours in a male patient with intracranial meningioma and pulmonary metastases, showing sheet-like growth and lobular arrangement of the tumour cells, with atypia and mitotic figures: (a) primary meningioma; (b) recurrent meningioma; (c) pulmonary metastasis, showing giant cells. Haematoxylin and eosin. Immunohistochemical staining in recurrent meningioma showing tumour cells positive for epithelial membrane antigen (d), Ki-67 (e) and progesterone receptor (f). The colour version of this figure is available at: <http://imr.sagepub.com>.

In December 2011, a small mass was noticed by the patient in the left occipital scalp. By April 2012 this had become much larger and the patient was readmitted to hospital. MRI showed a 5 × 5 × 5 cm homogeneously enhancing tumour in the left occiput region, suggestive of a recurrent meningioma. The patient also underwent whole-body \[^18^F\]-2-fluoro-2-deoxy-[d]{.smallcaps}-glucose positron emission tomography/computed tomography, which revealed multiple lesions in the right pulmonary lobe, the largest of which was 2.6 × 2 cm and located in the inferior lobe, with lymphadenectasis in the right hilus ([Figure 3](#fig3-0300060515618053){ref-type="fig"}). These multiple lesions were thought to be lung neoplasms or metastases from an unknown primary. A second craniotomy was performed and a well-demarcated subcutaneous mass was seen that had invaded the subcutaneous tissues, local skull and meninges. The tumour and the invaded meninges and skull were totally removed surgically. The postoperative pathological diagnosis was the same as before ([Figure 2b](#fig2-0300060515618053){ref-type="fig"},[d](#fig2-0300060515618053){ref-type="fig"}--[f](#fig2-0300060515618053){ref-type="fig"}). Figure 3.Whole-body \[^18^F\]-2-fluoro-2-deoxy-[d]{.smallcaps}-glucose positron emission tomography/computed tomography showing multiple lesions in the right pulmonary lobe in a male patient with intracranial meningioma. The colour version of this figure is available at: <http://imr.sagepub.com>.

The patient subsequently underwent removal of the lesions in the right lung 3 months after the second craniotomy. Unexpectedly, histological examination revealed different sized tumour cells arranged in sheets, with atypia and giant cells ([Figure 2c](#fig2-0300060515618053){ref-type="fig"}). Immunohistochemical staining demonstrated that the tumour cells were positive for epithelial membrane antigen, Ki-67 (\> 10%) and progesterone receptor, but were negative for S100, CK7, CK14, CD20 and CD3. The pathological diagnosis was metastatic meningioma. Because of residual lymphadenectasis in the right hilus after the thoracotomy, the patient was recommended to undergo chemotherapy but he refused. He therefore received radiotherapy at a dose of 60 Gy for the residual lymphadenectasis. Although the treatment given was not optimum, the patient has not developed any further recurrences or metastases to date.

The patient gave written consent for this case to be published.

Discussion {#sec3-0300060515618053}
==========

Multiple pulmonary metastases from intracranial meningiomas are rare. To the best of our knowledge, 35 cases of intracranial meningiomas with multiple pulmonary metastases have been reported since 1960 ([Table 1](#table1-0300060515618053){ref-type="table"}),^[@bibr7-0300060515618053][@bibr8-0300060515618053][@bibr9-0300060515618053][@bibr10-0300060515618053][@bibr11-0300060515618053][@bibr12-0300060515618053][@bibr13-0300060515618053][@bibr14-0300060515618053][@bibr15-0300060515618053][@bibr16-0300060515618053][@bibr17-0300060515618053][@bibr18-0300060515618053][@bibr19-0300060515618053][@bibr20-0300060515618053][@bibr21-0300060515618053][@bibr22-0300060515618053][@bibr23-0300060515618053][@bibr24-0300060515618053][@bibr25-0300060515618053][@bibr26-0300060515618053][@bibr27-0300060515618053][@bibr28-0300060515618053][@bibr29-0300060515618053][@bibr30-0300060515618053][@bibr31-0300060515618053][@bibr32-0300060515618053][@bibr33-0300060515618053]--[@bibr34-0300060515618053]^ with almost balanced sex distribution (18 male and 17 female cases), despite the fact that meningiomas are more common in women^[@bibr35-0300060515618053]^ and metastatic meningiomas are more common in men.^[@bibr36-0300060515618053]^ The median age of these patients was 50 years (age range 21--84 years. The interval from the time of detection of the primary intracranial meningioma to the detection of pulmonary metastases ranged between 2 months and 26 years, but five cases of pulmonary metastases were found concurrently with the primary intracranial meningioma^[@bibr11-0300060515618053],[@bibr14-0300060515618053],[@bibr28-0300060515618053][@bibr29-0300060515618053]--[@bibr30-0300060515618053]^ and one pulmonary lesion was identified first;^[@bibr12-0300060515618053]^ none of the 35 patients reported had obvious pulmonary symptoms such as cough or haemoptysis. Mostly the multiple metastases were located in both lungs; six cases, including the present case, were limited to the right lung^[@bibr9-0300060515618053],[@bibr12-0300060515618053],[@bibr22-0300060515618053],[@bibr26-0300060515618053],[@bibr31-0300060515618053]^ and one case of metastases was limited to the left lung.^[@bibr28-0300060515618053]^ The size of the largest metastasis was usually \>20 mm in diameter. Table 1.Reported cases of multiple pulmonary metastases in intracranial meningioma.ReferenceAge, yearsSexInterval, years^[a](#table-fn1-0300060515618053){ref-type="table-fn"}^Metastases, *n*^[b](#table-fn2-0300060515618053){ref-type="table-fn"}^Size, mm^[c](#table-fn3-0300060515618053){ref-type="table-fn"}^Location^[d](#table-fn4-0300060515618053){ref-type="table-fn"}^HistologyTreatment^[e](#table-fn5-0300060515618053){ref-type="table-fn"}^OutcomeKruse^[@bibr7-0300060515618053]^21Male10650Right occipitoparietalMeningothelialPartial resectionDied of convulsionAumann et al.^[@bibr8-0300060515618053]^45Female5Multiple20Left frontal parasagittalTransitionalTotal resectionNALeMay et al.^[@bibr9-0300060515618053]^56Female10MultipleNANABenignPartial resectionDied of disease 3 years after thoracotomyFukushima et al.^[@bibr10-0300060515618053]^50Male89NALeft posterior fossa with skull invasionPapillaryTotal resection and radiotherapyNANg et al.^[@bibr11-0300060515618053]^66MaleConcurrentMultiple15Parasagittal region of the left precentral gyrusTransitionalNADied of acute myocardial infarctionHishima et al.^[@bibr12-0300060515618053]^25FemalePrior to intracranial tumourMultiple50Right parietal region adjacent to the falxMeningothelialPartial resectionNAMurrah et al.^[@bibr13-0300060515618053]^53Female10945Left frontal hemispheric convexityNAPartial resectionAlive with disease 2 years after thoracotomyAdlakha et al.^[@bibr14-0300060515618053]^70MaleConcurrentMultipleNALeft frontal parasagittalPsammomatousResectionNo evidence of disease 7 years after thoracotomy39Female6MultipleNALeft parietal parasagittalAtypicalPartial resection and gamma knife radiosurgeryDied of disease 10 years after initial presentationFigueroa et al.^[@bibr15-0300060515618053]^50Female5MultipleNALeft cranial fossaTransitionalTotal resection and radiotherapy for metastasesAlive with disease 32 years after radiotherapyTravitzky et al.^[@bibr16-0300060515618053]^41Female19Multiple80NAMalignantTotal resection and radiotherapyNo evidence of disease 6 months after doxil-induced regression of metastasesTeague and Conces^[@bibr17-0300060515618053]^64Male2345BiparietalAtypicalResectionNAD'Aiuto et al.^[@bibr18-0300060515618053]^71Male133760Right temporo-occipitalAtypicalResectionNo evidence of disease 24 months after thoracotomyErman et al.^[@bibr19-0300060515618053]^34Female8MultipleNALeft frontal- parasagittalMeningotheliomatous/ atypicalPartial resection and radiotherapyDied of disease shortly after thoracotomy, radiotherapy and chemotherapy of the metastasesYekeler et al.^[@bibr20-0300060515618053]^43Male0.2Multiple30Right convexityNAResectionNAFabi et al.^[@bibr21-0300060515618053]^57Male12Multiple35Right frontalMalignantTotal resection and radiotherapyAlive with disease 6 months after diagnosis of metastasesGladin et al.^[@bibr22-0300060515618053]^47Male113Right frontalTransitionalTotal resectionNAAsioli et al.^[@bibr23-0300060515618053]^5812Multiple30NAMeningothelialResectionAlive with disease 18 months after thoracotomyIshibashi et al.^[@bibr24-0300060515618053]^68Male26Multiple60NANAResectionNAPsaras et al.^[@bibr25-0300060515618053]^65Female15MultipleNAFalx cerebri and superior sagittal sinusMeningothelialTotal resection and radiotherapyNo evidence of disease 12 months after thoracotomyEstanislau et al.^[@bibr26-0300060515618053]^75Male6MultipleNARight temporoparietalAtypicalTotal resectionDied about 30 days after radical resection surgery of cervical metastasisAlexandru et al.^[@bibr27-0300060515618053]^67MaleNANANABifrontalAnaplasticPartial resectionNA26FemaleNANANAMultiple supratentorialAnaplasticPartial resectionNA84FemaleNANANARight frontalNATotal resectionNA38MaleNANANARight and left sphenoid, cavernous sinusAtypicalPartial resectionNA52FemaleNANANARight frontal, left parietal and right occipitalAtypicalPartial resectionNA57MaleNANANARight parietal and right occipitalAnaplasticPartial resectionNASabet et al.^[@bibr28-0300060515618053]^62FemaleConcurrentMultipleNALeft frontalAnaplasticPartial resection and radiotherapyNACheng et al.^[@bibr29-0300060515618053]^46MaleConcurrent4NARight parietalBenignTotal resectionNo evidence of disease 5 months after chemotherapy and staged operations for pulmonary lesionsNakano et al.^[@bibr30-0300060515618053]^34Male0.3Multiple20Falx and superior sagittal sinusTransitionalTotal resectionNANakayama et al.^[@bibr31-0300060515618053]^25FemaleConcurrentMultiple30Right parietalMeningothelialTotal resectionNo evidence of disease 7 years after last surgeryOcque et al.^[@bibr32-0300060515618053]^47MaleNAMultipleNANAAtypicalNANA44FemaleNAMultipleNANAAnaplasticNANAFrydrychowicz et al.^[@bibr33-0300060515618053]^45Female5MultipleNALeft frontalAtypicalSurgery and radiotherapyNAGolemi et al.^[@bibr34-0300060515618053]^65MaleNAMultipleNANAAtypicalSurgery and gamma knife radiosurgeryNAPresent case59Male3Multiple26Left occiputAtypicalTotal resection and radiotherapyNo evidence of disease 3 years after thoracotomy[^1][^2][^3][^4][^5][^6]

The mechanism of multiple pulmonary metastases from intracranial meningiomas is unclear: there seems to be no constant relationship between the presence of metastases and the histological pattern of the intracranial meningioma. However, compared with meningiomas that do not metastasize at all or have a single metastasis, there are some predictive factors for multiple pulmonary metastases. First, atypical meningiomas have a greater tendency to be associated with multiple pulmonary metastases.^[@bibr14-0300060515618053],[@bibr17-0300060515618053][@bibr18-0300060515618053]--[@bibr19-0300060515618053],[@bibr26-0300060515618053],[@bibr27-0300060515618053],[@bibr32-0300060515618053][@bibr33-0300060515618053]--[@bibr34-0300060515618053]^ Venous sinus invasion may be another risk factor for multiple pulmonary metastases,^[@bibr8-0300060515618053],[@bibr11-0300060515618053],[@bibr12-0300060515618053],[@bibr14-0300060515618053],[@bibr19-0300060515618053],[@bibr25-0300060515618053],[@bibr27-0300060515618053],[@bibr30-0300060515618053]^ although in some cases, including the present case, the intracranial meningioma did not invade the sinuses. Prior surgery may damage the blood--brain barrier, promoting the spread of tumour cells. Intracranial tumour recurrence after the first craniotomy may be predictive of multiple metastases.^[@bibr9-0300060515618053],[@bibr12-0300060515618053],[@bibr15-0300060515618053][@bibr16-0300060515618053][@bibr17-0300060515618053][@bibr18-0300060515618053]--[@bibr19-0300060515618053],[@bibr22-0300060515618053],[@bibr25-0300060515618053],[@bibr27-0300060515618053],[@bibr31-0300060515618053],[@bibr33-0300060515618053]^ Furthermore, loss of heterozygosity at 9p, 1p and 22q has been reported to be a potential predictor of multiple pulmonary metastases.^[@bibr22-0300060515618053]^

Multiple pulmonary metastases are usually misdiagnosed as primary or metastatic adenocarcinoma, malignant mesothelioma or melanoma. Yekeler et al.^[@bibr20-0300060515618053]^ reported that similar signal features on MRI of pulmonary metastases and primary intracranial meningioma, including being isointense on T1- and T2-weighted images and late-phase contrast-enhanced T1-weighted images, might be predictive for diagnosis. Therefore, enhanced pulmonary computed tomography or MRI is recommended for patients with intracranial meningioma and risk factors for multiple pulmonary metastases. If available, positron emission tomography/computed tomography (PET/CT) is also valuable for diagnosis and follow-up after surgery.^[@bibr28-0300060515618053],[@bibr34-0300060515618053]^ However, PET/CT is not able to identify the cytopathology of pulmonary tumours, so the role of PET/CT in determining the presence of pulmonary metastatic meningioma remains controversial.

The standard treatment for multiple pulmonary metastases from intracranial meningioma has not been established by controlled studies. Commonly, the primary intracranial tumour is treated by surgical resection and postoperative radiotherapy is given for the prevention of local recurrence. It may be possible to perform thoracotomy to surgically remove the pulmonary metastases. However, if this is not feasible, chemotherapy is a valuable option for multiple pulmonary metastases. Travitzky et al.^[@bibr16-0300060515618053]^ reported that treatment with pegylated liposomal doxorubicin was associated with nearly complete resolution of a pulmonary metastasis in a patient with malignant meningioma. Other chemotherapies, including anthracyclines and alkylating agents, have shown some antitumour effect.^[@bibr21-0300060515618053]^ Sabet et al.^[@bibr28-0300060515618053]^ reported radioreceptor therapy using the radiolabelled somatostatin analogue ^177^Lu-DOTA-octreotate improved the health-related quality-of-life in a patient who had undergone multiple surgical resections and percutaneous radiation.

Due to the rarity of multiple pulmonary metastases in meningioma, it is difficult to study the long-term outcome. In most of the published reports, patients were alive with disease for \>18 months or without evidence of disease for \>12 months after thoracotomy. Nakayama et al.^[@bibr31-0300060515618053]^ reported a patient who had pulmonary and pleural metastases three times, and underwent resection of intracranial recurrences twice, who was alive 21 years after the first operation. The patient presented here has not developed any further recurrence or metastases to date.

In conclusion, blood-borne spread of tumour cells through venous channels is the most likely mechanism of pulmonary metastases in patients with meningioma. Atypical meningiomas, potential sinus invasion, tumour recurrence and loss of heterozygosity at 9p, 1p and 22q may be predictive of multiple pulmonary metastases. Treatment is mainly by surgical resection, with chemotherapy as a valuable option for multiple pulmonary metastases that cannot be totally removed. Enhanced pulmonary computed tomography is recommended for patients with intracranial meningioma and potential risk factors for multiple pulmonary metastases.
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